| Fathom Therapeutics: $47 Million Series A | series a | $47.0M | | Apr 27, 2026 |
| Fathom | | $47.0M | | Apr 27, 2026 |
| Fathom Therapeutics | series a | $47.0M | | Apr 27, 2026 |
| 10x Science: $4.8 Million | seed | $4.8M | InitializedY CombinatorCivilization Ventures+1 | Apr 26, 2026 |
| Kurma Partners | | $215.0M | | Apr 23, 2026 |
| CStone Pharmaceuticals | | $1.0B | | Apr 22, 2026 |
| UCL spinout QMatter | pre seed | $1.2M | | Apr 22, 2026 |
| 10x Science | | $4.8M | | Apr 22, 2026 |
| Ray Therapeutics | series b | $125.0M | | Apr 21, 2026 |
| Ray Therapeutics: $125 Million Series B | series b | $125.0M | Janus HendersonFranklin TempletonInvus+1 | Apr 21, 2026 |
| Pulnovo Medical scores $100M in oversubscribed finance | | $100.0M | | Apr 21, 2026 |
| Pulnovo Medical scores $100M in finance | | $100.0M | | Apr 21, 2026 |
| A new benchmark for biotech IPOs? Kailera | | $625.0M | | Apr 17, 2026 |
| In hopeful sign for biotech | | $625.0M | | Apr 17, 2026 |
| Sonire Therapeutics: $18 Million | series a | $18.0M | Santé Ventures | Apr 16, 2026 |
| Cambridge biotech STORM Therapeutics | series c | $56.0M | | Apr 16, 2026 |
| STORM Therapeutics | series c | $56.0M | | Apr 16, 2026 |
| STORM Therapeutics: $56 Million | series c | $56.0M | | Apr 16, 2026 |
| Harbinger Health | | $100.0M | | Apr 14, 2026 |
| Spiral Therapeutics | series b | $27.0M | | Apr 14, 2026 |
| Neomorph | | $100.0M | | Apr 13, 2026 |
| Vivatides | series a | $54.0M | | Apr 10, 2026 |
| Vivatides Therapeutics | series a | $54.0M | | Apr 10, 2026 |
| Vivatides Therapeutics: $54 Million | series a | $54.0M | | Apr 10, 2026 |
| The Week’s 10 Biggest | | $400.0M | | Apr 10, 2026 |
| Sidewinder Therapeutics | series b | $137.0M | | Apr 8, 2026 |
| Boston biotech co-founded by Harvard's David Sinclair | | $80.0M | | Apr 8, 2026 |
| Sidewinder Therapeutics: $137 Million | series b | $137.0M | | Apr 8, 2026 |
| Venture | | $100.0M | | Apr 6, 2026 |
| Opus Genetics | | $155.0M | | Apr 6, 2026 |
| Months after $100M series A | series a | $150.0M | | Apr 3, 2026 |
| Syneron Bio: $150 Million | series b | $150.0M | | Apr 3, 2026 |
| Paris-based Generare | series a | $20.0M | AlvenDaphni | Apr 2, 2026 |
| Semarion: University of Cambridge Spin-Out | | $3.8M | ParkwalkCambridge Enterprise VenturesOxford Innovation Finance+3 | Apr 1, 2026 |
| Semarion | | $2.9M | Parkwalk | Mar 31, 2026 |
| Semarion | seed | $3.8M | ParkwParkwalkCambridge Enterprise Ventures+4 | Mar 31, 2026 |
| Laigo Bio: €17 Million | seed | $17.0M | | Mar 31, 2026 |
| Amani Therapeutics: $25 Million | series a | $25.0M | | Mar 31, 2026 |
| Denali Therapeutics | | $200.0M | | Mar 31, 2026 |
| Centivax: $37 Million | | $37.0M | | Mar 30, 2026 |
| Cellbricks Therapeutics: €10 Million | | $10.0M | | Mar 30, 2026 |
| CROSSPOINT Therapeutics | series a | $2.4M | | Mar 30, 2026 |
| Pinnacle Medicines: $89 Million Series B | series b | $89.0M | LAVForesite Capital | Mar 29, 2026 |
| Crossbow Therapeutics | series b | $77.0M | | Mar 29, 2026 |
| Terrestrial Bio: $50 Million | series c | $50.0M | RA Capital | Mar 27, 2026 |
| USF-led dementia clinical trial | | $2.8M | | Mar 26, 2026 |
| Hyderabad-based biotech startup ELMED Life Sciences | | $2.7M | | Mar 26, 2026 |
| Cellbricks Therapeutics | seed | $10.0M | Silicon Roundabout Ventures | Mar 26, 2026 |
| A; Immutrin | series a | $87.0M | | Mar 25, 2026 |
| PE investor group | | $8.9B | Astorg | Mar 25, 2026 |